Proteomics International and PromarkerD at BIO 2019 saying 30 million diabetics in US deserve to know their future kidney dis...
June 03 2019 - 8:00AM
JCN Newswire (English)
|
- PromarkerD world's leading diagnostic test for
diabetic kidney disease says Frost & Sullivan industry report
'Biomarkers Enabling Diabetes and Obesity
Management'
|
Philadelphia, PA, June 3, 2019 - (ACN Newswire) -
Proteomics International (PILL; ASX: PIQ) will be at the 2019 BIO
International Convention in Philadelphia (stand #2349) preparing
for the US roll-out of PromarkerD, a blood test that can diagnose
and predict whether a healthy patient will develop diabetic kidney
disease.
"PromarkerD is world-beating technology and needs to get into the
hands of specialists and physicians to stem the tsunami of kidney
disease which is causing over 40,000 deaths per year in the US,
with related healthcare spending exceeding US$100 billion
annually."
"There is nothing else like PromarkerD available - it's the world's
leading predictive test for diabetic kidney disease according to
analysts in our sector," said Chuck Morrison, Proteomics
International's Head of Business Development, based in Boston. "The
US population with diabetes deserve to know their kidney disease
status."
He said the test will also make a major difference for insurance
companies because it will cut dramatically the number of people who
are unaware they have progressive kidney disease so they can do
something about it immediately, and so reduce treatments costs.
PromarkerD, rated the world's leading diagnostic test for diabetic
kidney disease by Frost & Sullivan in its independent industry
report titled 'Biomarkers Enabling Diabetes and Obesity
Management', has received patent protection in several major
jurisdictions including the USA, China, Europe, and Japan, with
others pending.
The Australian delegation to BIO 2019 is the largest to date, and
is among the ten largest this year, alongside 17,000 biotech and
pharma leaders from 70 countries. The Western Australian 'Think
Perth' delegation is led by the State's Deputy Premier and Minister
for Health, Hon Roger Cook, and Professor Peter Klinken, Chief
Scientist of Western Australia.
PromarkerD (www.PromarkerD.com)
PromarkerD is a predictive diagnostic test for diabetic kidney
disease. In clinical studies presented at the American Diabetes
Association Annual Scientific Sessions [ASX: 13 June 2017] and
published in the journal Diabetes Care [ASX: 6 Sept 2017],
PromarkerD correctly predicted 86% of previously kidney
disease-free diabetic patients who went on to develop chronic
kidney disease.
PromarkerD has been rated the world's leading diagnostic test for
diabetic kidney disease by global research house Frost &
Sullivan in its report 'Biomarkers Enabling Diabetes and Obesity
Management' [ASX: 27 March 2017]. PromarkerD has received patent
protection in several major jurisdictions including the USA, China,
Europe, and Japan, with others pending. Further information is
available at the PromarkerD web portal.
Proteomics International (www.proteomicsinternational.com)
Proteomics International Laboratories Ltd ('PILL'; ASX: PIQ) is a
medtech company at the forefront of predictive diagnostics and
bio-analytical services, focused on proteomics - the industrial
scale study of the structure and function of proteins. It received
the world's first ISO 17025 laboratory accreditation for proteomics
services, and operates from state-of-the-art facilities on QEII
Medical Campus in Perth, W. Australia.
Proteomics International is centred on commercialisation of its
world-leading test for diabetic kidney disease, PromarkerD. The
company offsets its R&D and product development cash flows with
provision of specialist analytical services, while using its
proprietary Promarker(TM) technology to create a pipeline of novel
diagnostic tests.
Please contact:
Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com
Chuck Morrison
Head of Business Development
Proteomics International
T: +1 617 331 2975
E: c.morrison@proteomicsinternational.com
Susan Fitzpatrick-Napier
Public Relations & Media Contact
Digital Mantra Group
T: +61 2 8218 2144 or +1 415 951 3228
E: team@dmgpr.com
Dirk van Dissel
Corporate Advisor & Investor Relations
Adelaide Equity Partners
T: +61 8 8232 8800
E: dvandissel@adelaideequity.com.au
Source: Proteomics International Laboratories Ltd (PILL)
Copyright 2019 ACN Newswire . All rights reserved. |
Proteomics International... (ASX:PIQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Proteomics International... (ASX:PIQ)
Historical Stock Chart
From Apr 2023 to Apr 2024